Clinical study on Bactiguard’s endotracheal tube now published – shows significant reduction of ventilator-associated pneumonia

Report this content

The VITAL study, by Professor Pierre Damas and his team, is now published in the well renowned journal Annals of Intensive Care. The study shows a 53% reduction of ventilator-associated pneumonia with Bactiguard’s endotracheal tube. It was presented for the first time at the European Society of Intensive Care congress (ESICM) in October 2021.

These are very important data for critically ill patients in need of mechanical ventilation. Ventilator-associated pneumonia (VAP) is an unwanted complication associated with increased hospital length-of-stay, increased costs and increased mortality. The study data indicates that by using a Bactiguard endotracheal tube the risk of this complication is significantly reduced”, says Professor Pierre Damas.

“We are very happy for this publication of the first well-designed study with clinical relevant endpoints on the Bactiguard endotracheal tube. The previous extensive evidence on the Bactiguard technology has been broadened, and to date we have seen meaningful clinical results regardless of application area", says Stefan Grass, Chief Medical Officer and Deputy CEO.

The study was a randomized-controlled double-blinded study including 323 patients, either intubated with a Bactiguard endotracheal tube or a conventional tube (both with subglottic suctioning port). The number of VAP cases were 22.4 per 1000 ventilator days in the control group compared with 10.5 in the Bactiguard group which was just short of significance (p=0.07). The time to occurrence of VAP was significantly reduced in the Bactiguard group (p=0.02).

The VITAL study was presented for the first at the European Society of Intensive Care congress (ESICM) 2021, where it was selected as one of the top 6 best abstracts. It is now published in Annas of Intensive Care: https://rdcu.be/cEo77

About BIP Endotracheal Tube Evac

Bactiguard’s BIP ETT Evac is the only tube on the market that combines the subglottic secretion drainage with the clinically proven ability of the Bactiguard technology to reduce microbial adhesion The technology is based on a very thin noble metal alloy coating, firmly attached to the tube surface. When in contact with fluids, the noble metals create a galvanic effect which reduces microbial adhesion. This means that less bacteria adhere to the tube surface, which reduces the risk of biofilm formation leading to infection.


For more information, please contact:
Stefan Grass, Chief Medical Officer and Deputy CEO, mobile +46 70 725 24 48
 

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with the Bactiguard technology are market leading in the USA and Japan through our licensing partner BD, and in 2021 orthopaedic trauma implants, ZNN Bactiguard, were launched by Zimmer Biomet. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills microbes while being biocompatible and tissue friendly.

Bactiguard is in a strong expansion phase in the markets in Europe, China, India, the Middle East and Southeast Asia through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 210 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about Bactiguard www.bactiguard.com